Know Cancer

or
forgot password

A Phase II Open-Label Trial of AUY922, an HSP90 Inhibitor, in Patients With ALK-Rearranged Advanced Non-Small Cell Lung Cancer and Acquired Resistance to Prior ALK Tyrosine Kinase Inhibition


Phase 2
18 Years
N/A
Open (Enrolling)
Both
Non Small Cell Lung Cancer

Thank you

Trial Information

A Phase II Open-Label Trial of AUY922, an HSP90 Inhibitor, in Patients With ALK-Rearranged Advanced Non-Small Cell Lung Cancer and Acquired Resistance to Prior ALK Tyrosine Kinase Inhibition


If you agree to participate in this research study, you will be asked to undergo some
screening tests or procedures to find out if you can be in the research study. Many of these
tests and procedures are likely to be part of regular cancer care and may be done even if it
turns out that you do not take part in the research study. If you have had some of these
tests or procedures recently, they may or may not have to be repeated. These test include a
medical history, physical exam, performance status, assessment of tumor, EKG, echocardiogram
or multigated acquisition scan, eye exam, blood draw, blood pregnancy test, urine tset and
collection of a piece of stored tumor tissue. If these tests show you are eligible to
participate in the research study, you will begin the study treatment. If you do not meet
the eligibility criteria, you will not be able to participate in this research study.

Study treatment is given in 21 day cycles. AUY922 is given by IV (into a vein). This is
called an infusion. You will receive an infusion of AUY922 jon days 1,8 and 15 of each cycle
(once per week). The infusion will take about 60 minutes.

A schedule of clinic visits for the study is summarized below. At every visit, you should
tell the study staff how you are feeling and whether your health has changed. you may have
other lab tests done as part of the the care of your cancer in addition to those listed
below.

Cycle 1, Day 1: physical examination, performance status, EKG, Blood draw and routine urine
tests.

Cycle 1, Day 2: EKG

Cycle 1, Day 3: EKG

Cycle 1, Day 8: measurement of weight and vital signs, performance status, EKG, questions
about side effects you may have and medications you are taking

Cycle 1, Day 15: physical exam, performance status, EKG, blood draw, questions about side
effects you may have and medications you are taking.

Note that in Cycle 1 you will need to stay at (or return to) the clinic for the last EKG
following the Day 1 AUY922 infusion, and come to the clinic on Days 2 and 3 for EKGs

Cycle 2 and beyond, Day 1: physical exam, performance status, EKG, blood draw, questions
about side effects you may have and medications you are taking, routine urine test

Cycle 2 and beyond, Day 8: measurement of weight and vital signs, performance status, EKG,
questions about side effects and medications

Cycle 2 and beyond, Day 15: physical exam, vital signs, performance status, EKG, blood draw,
questions about side effects and medications

Additional EKGs may be done at any time if your study doctor thinks it is necessary. A blood
test to measure the amount of cardiac enzymes in your blood may be done whenever abnormal
findings such as heart rhythm changes are suspected or seen on the EKG. CT or MRI scans will
be done to measure your disease about every 6 weeks. A blood pregnancy test, for women who
can become pregnant, will be performed every 6 weeks or at any point in which pregnancy is
suspected. A standard eye exam will be done on Cycle 3, Day 1. Additional eye exams will be
done if you experience any eye-related symptoms, such as changes in vision.

Within 1 week after your last dose of the study drug AUY922, you will be asked to return to
the clinic for an End of Treatment Visit. At this visit the following will be done: physical
examination, performance status, ECG, ECHO or MUGA scan, blood draw, urine test, eye exam,
questions about side effects you may have and medications you are taking.

You will be asked to return to the clinic about 3 weeks after the End of Treatment Visit
(about 4 weeks after the last dose of AUY922) so we can follow-up on any side effects you
may still be experiencing after stopping AUY922.

If you decide to stop study treatment for a reason other than progression of your disease,
you will be asked to have follow-up CT scans or MRIs every 12 weeks to continue to monitor
the status of your cancer. If your tumors get worse, you will not need to have any further
CT scans (or MRIs) as part of the study.

If your disease does progress, we would like to contact you by telephone about every 3
months to check on your status. This will be done until after the last participant stops
study treatment, or for as long as you allow us to contact you. Keeping in touch with you
and checking on your condition helps us look at the long term effects of the research.

You can continue to receive AUY922 for as long as your cancer does not progress and you do
not experience unacceptable side effects.


Inclusion Criteria:



- Histologically or cytologically confirmed advanced NSCLC

- Tumor characterized by abnormalities in ALK

- Required to provide archival tissue in the form of 5 formalin fixed paraffin embedded
sections

- Have acquired resistance to treatment with an ALK-TKI

- At least one measurable lesion as defined by RECIST criteria

- Life expectancy of at least 12 weeks

Exclusion Criteria:

- Pregnant or breastfeeding

- Discontinued ALK TKI more than four weeks prior to enrollment

- Unresolved diarrhea greater than or equal to CTCAE grade 1

- Not willing to use double barrier methods of contraception

- Prior anti-neoplastic treatment with any HSP90 or HDAC inhibitor compound

- Have received cytoxic chemotherapy in the intervening period since discontinuation of
an ALK-TKI

- Have undergone major surgery within 2 weeks prior to starting study drug

- Any concurrent or uncontrolled illness

- Any known disorders due to a deficiency in bilirubin glucuronidation

- Taking therapeutic doses of warfarin

- Any serious cardiac disorders or abnormalities

- Concurrent malignancies or invasive cancers diagnosed within the past 2 years except
for adequately treated basal cell cancer of the skin or in situ cancers

- Known to be HIV positive

- Known hypersensitivity to any of the study drugs or their excipients

- Participation in another clinical study within 30 days before the first study
treatment

Type of Study:

Interventional

Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Objective Response Rate

Outcome Description:

Evaluate the best objective response rate to AUY922

Outcome Time Frame:

2 years

Safety Issue:

No

Principal Investigator

Alice Shaw, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Massachusetts General Hospital

Authority:

United States: Food and Drug Administration

Study ID:

12-458

NCT ID:

NCT01752400

Start Date:

January 2013

Completion Date:

Related Keywords:

  • Non Small Cell Lung Cancer
  • Advanced
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location

Dana-Farber Cancer InstituteBoston, Massachusetts  02115
Brigham and Women's HospitalBoston, Massachusetts  02115
Massachusetts General HospitalBoston, Massachusetts  02114-2617
Beth Isreal Deaconess Medical CenterBoston, Massachusetts  02215